Dewpoint Therapeutics

Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Corporation Enter Research Collaboration to Advance Small Molecule Condensate Modulator for ALS

Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying pathology of <97% of ALS patients Mitsubishi Tanabe Pharma Corporation obtains an option for a global license to develop and commercialize the novel TDP-43 small molecule condensate modulator Deal valued at up to $480 million-...
Dewpoint Therapeutics 451 D Street, Suite 104 Boston, MA 02210 USA